Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.
Cancer Res. 2011 Dec 15; 71(24):7513-24
J Alan Diehl and Eric K Lee
08 Dec 2011
|
Controversial, New Finding, Novel Drug Target
In this work, Zhang et al. demonstrate that cyclin D1 is dispensable for ErbB2-driven mammary tumorigenesis. Additionally, temporal loss of cyclin D1 after tumor initiation had no effect on orthotopic tumor growth. Cyclin D1-null ErbB2-driven carcinomas exhibited elevated cyclin D3 levels and ErbB2 overexpression in clinical samples...
INDIVIDUAL SUBSCRIPTIONS
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.
Subscribe for $9.95/monthINSTITUTIONAL SUBSCRIPTIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
Recommend to your LibrarianIf you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.
Request an Institutional Trialyour institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.